Aligos Therapeutics ALGS

NASDAQ ALGS
$2.10 +0.12 (+6.06%)
At close: Nov 13, 2026 · 4:00 PM EST

Aligos Therapeutics (ALGS) stock price is $2.10, up 6.06% on the day, as of Nov 13, 2026. It has a market cap of $21.97Mn, and is classified in the Biotechnology industry (Healthcare sector).

Key Stats
Market Cap21.97 Mn
P/E-0.33
FCF (Yr)-82.07 Mn
ROA (Yr)-30.48
EV to EBIT4.34
Net Income (Yr)-24.19 Mn
Enterprise Value-314.86 Mn
Add ratio to table…

About

Aligos Therapeutics, Inc. is a clinical stage biotechnology company that was founded in February 2018 and is headquartered in South San Francisco California. The company focuses on discovering and developing new treatments for liver diseases and viral infections with an emphasis on conditions that have high unmet medical need. Its primary areas of interest are chronic hepatitis B virus infection, metabolic dysfunction associated steatohepatitis (MASH), obesity and…

Read more ↓
Sector: Healthcare Sector rationale Aligos Therapeutics is a clinical-stage biotechnology company focused on discovering and developing treatments for liver diseases and viral infections, such as hepatitis B and SARS-CoV-2. Its business model involves advancing drug candidates (small molecules and oligonucleotides) through clinical trials, with revenue currently derived from licensing agreements, research grants, and milestone payments typical of the Biotechnology industry. Industry: Biotechnology Biotechnology Primary Aligos Therapeutics is a clinical-stage biotechnology company developing therapies derived from biological science, specifically oligonucleotide candidates and small molecules for liver diseases and viral infections. Its revenue is currently derived from collaborations, licensing agreements, and milestone payments, which is characteristic of the H-02 classification. Classified using BQ-MICS CIK: 0001799448
Peer percentiles

How Aligos Therapeutics ranks

Ranked against the 695 companies in Pharmaceuticals and Biotechnology58 metrics · as of Nov 14, 2026

Valuation

12 metrics · Lower multiples rank higher; a negative multiple ranks last
  • P/ENegative earnings −0.33xMedian 17.0x 12th
  • P/FCFNegative free cash flow −0.32xMedian 19.0x 9th
  • P/Operating cash flowNegative operating cash flow −0.32xMedian 16.4x 9th
  • P/S 3.77xMedian 8.38x 65th
  • P/B 1.94xMedian 2.04x 53rd
  • P/Tangible book 1.94xMedian 2.31x 56th
  • EV/EBITDANet cash exceeds market value 0.13xMedian 14.6x Not meaningful —
  • EV/EBITNet cash exceeds market value 0.13xMedian 18.4x Not meaningful —
  • EV/RevenueNet cash exceeds market value −1.57xMedian 6.34x Not meaningful —
  • EV/FCFNet cash exceeds market value 0.13xMedian 23.4x Not meaningful —
  • EV/Operating cash flowNet cash exceeds market value 0.13xMedian 19.3x Not meaningful —
  • PEG (3Y EPS CAGR)Negative earnings 0.01Median 0.43 Not meaningful —
Peer group

Peer Comparison

Companies in the Biotechnology
View all peers
S.No. Ticker Company Market CapP/EP/STotal Debt (Qtr)
1 LLY ELI LILLY & Co 1,359.75 Bn46.7415.7349.50 Bn
2 JNJ Johnson & Johnson 688.76 Bn42.836.9344.65 Bn
3 ABBV AbbVie Inc. 521.69 Bn50.487.9080.90 Bn
4 MRK Merck & Co., Inc. 364.31 Bn148.685.4153.78 Bn
5 NVS Novartis Ag 306.35 Bn17.915.08-
6 AZN Astrazeneca Plc 285.96 Bn25.924.82-6.68 Bn
7 AMGN Amgen Inc 251.88 Bn26.836.4754.01 Bn
8 ALGS Aligos Therapeutics, Inc. 0.02 Bn-0.333.77-